Dermata Therapeutics, Inc. (DRMA) vs GRI Bio, Inc. (GRI)
Over the past 5 years, DRMA outperformed GRI — -83.90% vs -95.39% annualized total return (price plus dividends).
A side-by-side comparison of Dermata Therapeutics, Inc. and GRI Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — DRMA vs GRI
growth of $100 · dividends reinvested · last 5yMetrics side by side
Did DRMA beat GRI?
Over the past 5 years, DRMA outperformed GRI — -83.90% vs -95.39% annualized total return (price plus dividends).
Total return (annualized)
| Metric | DRMA | GRI |
|---|---|---|
| Total return (1Y) | -77.00% | -96.44% |
| Total return CAGR (3Y) | -80.18% | -97.04% |
| Total return CAGR (5Y) | -83.90% | -95.39% |
GRI is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has DRMA beaten GRI?
- Over the past 5 years, DRMA outperformed GRI — -83.90% vs -95.39% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.